Literature DB >> 10527224

The safety and effectiveness of esmolol in the perioperative period in patients undergoing abdominal aortic surgery.

T N Harwood1, J Butterworth, R C Prielipp, R L Royster, K Hansen, G Plonk, R Dean.   

Abstract

OBJECTIVES: To determine (1) if perioperative use of esmolol in major vascular surgery patients provides strict heart rate (HR) control, (2) what doses of esmolol are required to do this, and (3) does this control influence myocardial ischemia or result in adverse consequences.
DESIGN: Prospective study of 40 patients randomized to two groups: The HR was controlled to either less than 80 beats/min (group 80) or less than 110 beats/min (group 110) using esmolol. Patients were monitored continuously for electrocardiographic changes perioperatively. HR control began after induction of anesthesia and continued for 48 hours thereafter.
SETTING: Operating room and intensive care unit. PATIENTS: Patients undergoing abdominal vascular surgery involving aortic cross-clamping.
INTERVENTIONS: Esmolol was titrated until the target HR was met. MEASUREMENTS AND
RESULTS: Only one patient demonstrated an adverse effect. The median infusion rates were 100 and 12.5 microg/kg/min for groups 80 and 110. Target HR was met less in group 80 than in group 110, primarily in the postoperative period. Ischemia patterns were not significantly different between groups.
CONCLUSION: Using esmolol for HR control in the intraoperative period for abdominal vascular surgery patients is effective and safe. HR control was much less effective in the postoperative period, but esmolol is safe when used at recommended doses. Further study with a larger number of patients is necessary to determine whether strict HR control with esmolol affects the incidence of myocardial ischemia or infarction in this patient population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527224     DOI: 10.1016/s1053-0770(99)90007-1

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  4 in total

1.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

2.  Answering letter to remark of Dr's Frank and Fitzgerald.

Authors:  Günther Krumpl
Journal:  Eur J Clin Pharmacol       Date:  2018-01-10       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and therapeutic efficacy of esmolol.

Authors:  Donald B Wiest; Jason S Haney
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

4.  Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Authors:  Günther Krumpl; Ivan Ulč; Michaela Trebs; Juri Hodisch; Pavla Kadlecová; Bernhard Husch
Journal:  Cureus       Date:  2020-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.